The findings indicate that autologous NK cells activated ex vivo with TKD/IL‐2 are well‐tolerated and yield favorable clinical outcomes in patients with advanced NSCLC post‐radiochemotherapy [155]. The gene discussed is IL2; the disease is non-small cell lung carcinoma.